Sage/Biogen Depression Data Likely To Prolong Commercial Debate

Debate over the commercial viability of Sage Therapeutics, Inc./Biogen, Inc.’s zuranolone isn’t getting any quieter as additional data rolls in. The Phase III CORAL study in major depressive disorder (MDD) met its primary endpoint of rapid onset of anti-depressant effect, with an acceptable safety and tolerability profile, but missed a key endpoint on durability.

The companies unveiled the CORAL data on 16 February, saying that the trial met its primary endpoint of a rapid...